GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Other Operating Expense

Nova Mentis Life Science (Nova Mentis Life Science) Other Operating Expense : $0.14 Mil (TTM As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Other Operating Expense?

Nova Mentis Life Science's Other Operating Expense for the three months ended in Sep. 2023 was $0.04 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.14 Mil.

Nova Mentis Life Science's quarterly Other Operating Expense declined from Dec. 2022 ($0.06 Mil) to Mar. 2023 ($0.04 Mil) but then increased from Mar. 2023 ($0.04 Mil) to Sep. 2023 ($0.04 Mil).

Nova Mentis Life Science's annual Other Operating Expense increased from Dec. 2020 ($0.19 Mil) to Dec. 2021 ($0.23 Mil) but then declined from Dec. 2021 ($0.23 Mil) to Dec. 2022 ($0.19 Mil).


Nova Mentis Life Science Other Operating Expense Historical Data

The historical data trend for Nova Mentis Life Science's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Other Operating Expense Chart

Nova Mentis Life Science Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.20 0.19 0.23 0.19

Nova Mentis Life Science Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.06 0.06 0.04 0.04

Nova Mentis Life Science Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nova Mentis Life Science Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Nova Mentis Life Science (Nova Mentis Life Science) Headlines

From GuruFocus

Nova Mentis Begins Enrollment in North American Autism Study

By PRNewswire PRNewswire 03-23-2022